Fierce Biotech unveils M&A tracker

Today's Big News

May 17, 2023

Intercept's latest NASH bid in jeopardy after FDA questions drug's efficacy, safety


Theranos’ Holmes ordered to report to prison amid appeal, fined $452M in restitution alongside Balwani


Fierce Biotech M&A Tracker 2023: Gilead nabs PARP1 specialist, Bellus, Satsuma and more


Allergan's new skin-smoothing product gets FDA nod—with novel delivery mechanism


Pfizer's maternal RSV vaccine appears to win over FDA ahead of advisory meeting


Intuitive Surgical CEO hands off president title to longtime company vet Dave Rosa

 

Featured

Intercept's latest NASH bid in jeopardy after FDA questions drug's efficacy, safety

Citing a long list of safety risks and the practical hurdle for patients to undergo a liver biopsy, the FDA said it “cannot justify OCA use in NASH subjects with stage 2 or 3 fibrosis.”
 

Top Stories

Theranos’ Holmes ordered to report to prison amid appeal, fined $452M in restitution alongside Balwani

Elizabeth Holmes’ last-ditch effort to avoid prison time while appealing her fraud convictions was denied this week, paving the way for her 11-year sentence to begin.

Fierce Biotech M&A Tracker 2023: Gilead nabs PARP1 specialist, Bellus, Satsuma and more

Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe.

Allergan's new skin-smoothing product gets FDA nod—with novel delivery mechanism

Joining Allergan's Juvederm brand is Skinvive, which smooths facial skin via hyaluronic acid intradermal microdroplet injection, according to the company.

Pfizer's maternal RSV vaccine appears to win over FDA ahead of advisory meeting

The FDA seems to be satisfied that Pfizer's RSV vaccine is safe and effective for administration in pregnant women to protect infants from severe disease.

Intuitive Surgical CEO hands off president title to longtime company vet Dave Rosa

Amid a period of rapid growth for Intuitive Surgical, the robotics maker is also expanding its power structure.

Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say

News of the Federal Trade Commission (FTC) lawsuit challenging Amgen’s $28 billion buyout of Horizon prompted an immediate question: Will the U.S. antitrust enforcer also attempt to derail Pfizer’s plan to acquire Seagen for $43 billion? Analysts at Berenberg Capital Markets say don’t automatically assume that Pfizer-Seagen will face the same hurdle.

DeepIntent, Roku pitch 'silver streamers' as golden opportunity for pharma ad campaigns

DeepIntent and Roku want to challenge the idea that watching TV on streaming services is the preserve of the young. With 79% of people aged 50 and up using the services, adults in the core demographics for many drug products are streaming and open to viewing ads.

After safety signals snare rivals, Roche's MS drug clears lesions without the adverse events

Roche’s BTK inhibitor has hit the mark in a midphase multiple sclerosis trial—and without causing the sort of adverse events that sparked partial holds on Merck KGaA and Sanofi’s rival assets.

Waxing Moon: Surgical tech maker pulls $55M and robotics maven Moll into its orbit

With a fresh injection of venture funding and a high-profile addition to its board, Moon Surgical is entering a new phase.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The final installment of a series on Narcan, plus this week's headlines

This week on "The Top Line," we're concluding our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.
 

Resources

Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events